CliffBio
small molecule

SPIRIVA

TIOTROPIUM BROMIDE

Loss of exclusivityJuly 2026latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →View the full company profile on CliffBio

Drug detail

Brand nameSPIRIVA
Active ingredientTIOTROPIUM BROMIDE
StrengthEQ 0.018MG BASE/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalJanuary 2004
Marketing statusRX

Listed patents

PatentExpiresType
8022082*PEDJuly 2026—
8022082January 2026product

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SPIRIVA patent cliff — loss of exclusivity July 2026 | CliffBio